Norstella：2025破局自免药物商业化：基于真实世界数据的许可交易策略与案例解码报告（英文版）（17页）.pdf

1、Citeline|Evaluate Consulting&AnalyticsMarch 2025破局自免破局自免药物商业化药物商业化:基于真基于真实世界数据的许可交易策略与案例解码实世界数据的许可交易策略与案例解码The capabilities and experiences of the Citeline and Evaluate consulting organizations are now combinedWe answer key asset,portfolio,and corporate strategy-related business questions,powered by

2、 the combined resources of Norstella,one of the worlds largest pharma intelligence solutionsprovidersWith a team of 70 consultants globally,extensive data assets,and experience across therapy areas and modalities,we specialize in the areas of Asset&Portfolio Strategy,Licensing&Transaction Advisory,C

3、ompetitive Intelligence,Clinical Strategy&Planning,and Global Market AccessLinking evidence and impact:HEOR/RWE Studies,Analytical InsightsEmpowering access:Specialty Care Market Access ConsultingUS Formulary/Market Access Data,KOL and Payer Networks,Market Access InsightsPipeline Data,Consensus For

4、ecasts,Epi data,Commercial Strategy ConsultingConsulting&AnalyticsClinical Trials,RWD,Commercial Intelligence,Clinical and Commercial ConsultingPipeline Data,Consensus Forecasts,Epi data,Commercial Strategy ConsultingEmpowering access:Specialty Care Market Access ConsultingUS Formulary/Market Access

5、 Data,KOL and PayerNetworks,MarketAccess InsightsPanalgoLinking evidence and impact:HEOR/RWE Studies,Analytical InsightsSmoothing the path to life-saving treatment:from Pipelineto PatientBD&L Strategy support powered by the combined resources of Norstella23We have 20+years of experience working clos

6、ely with over 500+clients across all strategic altitudesOur offeringsStrategic altitudeProduct levelCross-portfolio/corporate levelIndustry levelOpportunity assessmentTPP testing KOL interviewsPricing strategy payer interviews and pharmacoeconomic modelingClinical planningTrial benchmarking and land